Teva Pharmaceutical Industries Limited

Technion Research & Development Foundation Limited

Other

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Ruth Levy

John P Finberg

Haim Yellin

Moussa B Youdim

Jeffrey Sterling

Alex Veinberg

David Lerner

Sasson Cohen

Jeff Sterling

Tirtsah Berger-Paskin

Yaacov Herzig

John P M Finberg

Moussa B H Youdim

Eran Blaugrund

Mitchell Shirvan

Eldad Melamed

Liat Hayardeny

Tzipora Speiser

Mussa B Youdim

Musa Youdim

Arieh Gutman

Willy Goldenberg

Dafna Atlas

Nava Shterman

Sela Yoram

Gabriela Barak

Rivka Kreitman

Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

Use of rasagiline for the treatment of restless legs syndrome

Methods for the treatment of Restless Legs Syndrome using R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

Use of rasagilline for the treatment of restless legs syndrome

The subject invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject in need of such treatment comprising administering to the subject R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof alone or in combination with 2-amino-6-trifluoromethoxy benzothiazole in amounts effective to treat ALS in the subject.

Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis

The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.

Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof

The subject invention provides R(&plus;)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(&plus;)-N-propargyl-1-aminoindan, or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(&plus;)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan

Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula:

Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives

Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder

The subject invention provides R(&plus;)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing the same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(&plus;)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject.

Pharmaceutical compositions for the treatment of a neurological disorder of neurotrauma or for improving memory in a patient comprising a therapeutically effective amount of S-(&minus;)-N-proparygl-1-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically active carrier. The pharmaceutical compositions are adapted, in particular for treating a neurological hypoxia or anoxia, neurodegenerative diseases. Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage.

Pharmaceutical compositions comprising S-(&minus;)-N-propargyl-1-aminoindan

Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula: ##STR1##

Compositions containing and methods of using 1-aminoindan and

This invention relates to the use of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof for the treatment of dementia.

R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia

The present invention provides a pharmaceutical composition contains a thpeutically effective amount of L-DOPA ethyl ester and a carrier which comprises from 5.5 to 98.5% hydroxypropylmethyl cellulose, from 0.25 to 4.5% hydroxypropyl cellulose, and from 1 to 90% of a carboxyvinyl polymer.

Pharmaceutical composition of L-DOPA ester

The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.

Growing community of inventors

Tel Aviv, Israel

Ruth Levy